

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Fondation Plan Alzheimer | GE Healthcare | Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2014
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Fondation Plan Alzheimer | GE Healthcare | Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Florbetapir Calibration to the Centiloid Scale
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 23, 2014
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Feasibility of Florbetapir Quantitation in Europe
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2014
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2014
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2013
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 13, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Florbetapir (18F) in Japanese Healthy Volunteers
Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Alzheimer's Drug Discovery Foundation | Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Brain Beta-Amyloid on Postoperative Cognition
Details : Florbetapir F 18 is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Cognitive Complications.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Alzheimer's Drug Discovery Foundation | Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of PET Scan Timing Relative to AV-45 Injection Time
Details : Florbetapir F 18 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2012
Lead Product(s) : Florbetapir F 18
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
